An Easy Landing? Cephalon Scores Priority Review For Nuvigil In Jet Lag Disorder
This article was originally published in The Pink Sheet Daily
Executive Summary
Some, however, remain skeptical of the medicine's potential after the Provigil patent expires.
You may also be interested in...
FDA Pushes Back Action Date For Nuvigil Label Expansion Due To New Data
Cephalon, which has positioned Nuvigil to replace Provigil as the latter sleep drugs faces patent expiry, hopes to add treatment of jet lag to label.
FDA Pushes Back Action Date For Nuvigil Label Expansion Due To New Data
Cephalon, which has positioned Nuvigil to replace Provigil as the latter sleep drugs faces patent expiry, hopes to add treatment of jet lag to label.
Priority Review's Luster Dims In "Safety First Era" But Retains Value - Parexel
Sponsors of the most innovative new drugs should not be deterred by the apparent reversals of fortune for new molecular entities with priority review status in the last year, the consulting firm Parexel concludes in a new report